Management to Host Conference Call to Review Q3 Financial Results
Management to Present at Deutsche Bank 39th Annual Health Care Conference
ATLANTA, April 29, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Tuesday, May 6, 2014 at 4:30 p.m. EDT to review the Company's third quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
To access the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international). Additionally, a live audio webcast of the call and the archived webcast will be available in the Investors section of the Biota website at http://www.biotapharma.com.
The Company also announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8th at 2:10 pm at the Intercontinental Hotel in Boston.
The presentation will be webcast live and may be accessed through the Investor Relations' Events and Presentations section on Biota's website at www.biotapharma.com. Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. An archived replay will also be available for 90 days following the live presentation.
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates: laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) intended to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus. In addition to these clinical-stage development programs, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus. For additional information about the Company, please visit www.biotapharma.com.
Source:Biota Pharmaceuticals, Inc